The diversity of (68)Ga-based imaging agents

Area of Science:

• Nuclear medicine
• Radiopharmaceutical development
• Positron Emission Tomography (PET) imaging

Background:

• Clinical nuclear medicine expansion relies on novel radiopharmaceuticals.
• Gallium-68 (68Ga)-based imaging agents for PET are rapidly increasing.
• 68Ga offers potential as a PET analog to 99mTc, with enhanced sensitivity, resolution, and quantitative capabilities.

Purpose of the Study:

• To highlight the increasing role of 68Ga in developing new PET imaging agents.
• To showcase the versatility of 68Ga for labeling various molecules and particles.
• To emphasize the potential of 68Ga to advance PET diagnostics and personalized medicine.

Main Methods:

• Review of existing and emerging 68Ga-based tracers for targeted, pretargeted, and nontargeted imaging.
• Discussion of automated, Good Manufacturing Practice (GMP)-compliant tracer production technologies.
• Exploration of 68Ga's advantages over traditional imaging modalities.

Main Results:

• 68Ga can label a wide array of molecules (small organic molecules, peptides, proteins, oligonucleotides) and particles.
• GMP-compliant automated production facilitates new radiopharmaceutical introduction and multicenter studies.
• 68Ga-based agents demonstrate potential for higher sensitivity, resolution, quantitation, and dynamic scanning compared to 99mTc.

Conclusions:

• 68Ga is a promising radionuclide for developing clinically practical PET agents.
• Automated production technologies support standardized multicenter studies and regulatory approval.
• The widespread adoption of 68Ga-PET can lead to earlier, better diagnostics and personalized medicine globally.